COPD and Inflammatory Mediators

Not Applicable

• Conditions: COPD
• Interventions: Other: exercise training

• Registration Number: NCT04271124
• Lead Sponsor: Faculty of Medicine, Sousse

Brief Summary

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020.

Detailed Description

COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversible.Not only the long-term exposition to noxious particles and gases contributes to the development of COPD, but also many others factors such as genetics and cigarette smoking. Cigarettes are harmful and contribute to different extra pulmonary disorders. Although COPD affects lungs some extrapulmonary manifestations are prescribed such as muscle dysfunction, abnormal respiratory muscles and systemic inflammation. Indeed, the systemic inflammation\[6, 8\] is considered as a key process in the pathogenesis of COPD. It involves different cells and molecules; high levels of circulating of white blood cells, increased plasma c-reactive proteins (CRP), interleukin 6 (Il6) have been reported in.those patients.Likewise, systemic inflammation could worsen the comorbidities (cardiovascular, osteoporosis..) and may lead to the exercise limitation.

Study Timeline

• Status Verified: 2020-01
• Study First Submitted: 2020-01-30
• Study First Submitted QC: 2020-02-13
• Last Update Submitted: 2020-02-13
• Study First Posted: 2020-02-17
• Last Update Posted: 2020-02-17
• Study Start: 2020-05
• Primary Completion: 2020-07
• Study Completion: 2020-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

• COPD diagnosed by pulmonary function testing
• Clinically stable
• Abscence of other obstructive diseases
• Signed written consent

Exclusion Criteria

• Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions
• cardiovascular diseases.
• Contre-indications to physical therapy
• Acute exacerbations a month before the intervention

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
PR+ET	exercise training	-
PR	exercise training	-

Primary Outcome Measures

Name	Time	Method
Change of Interleukins concentrations	Before the training, 2 months	ELISA assay

Secondary Outcome Measures

Name	Time	Method
6Minutes Walk test	Before the training, 2 months	patients performed the test

Trial Locations

Locations (1)

Laboratoire de Recherche : Physiologie de l'Exercice et Physiopathologie; 🇹🇳 Sousse, Tunisia